A Mechanism For The Development Of Obesity-associated Conditions Aug 6, 2008
Osei-Hyiaman et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. Journal of Clinical Investigation, 2008; DOI. (Science Daily)
Turned-off cannabinoid receptor turns on colorectal tumor growth Aug 1, 2008
They found that mice prone to developing intestinal tumors that also have functioning CB1 receptors develop fewer and smaller tumors when treated with a drug that mimics a cannabinoid receptor ligand ... Treating mice that had the CB1 receptor with an endocannabinoid agonist resulted in a decline in polyps ranging from 16 ... "Just increasing the levels of cannabinoids to treat colorectal cancer won't work if the CB1 receptor is not present," DuBois said. (EurekAlert!)
Why Cannabis Stems Inflammation Jul 22, 2008
Whilst the CB1 receptor in the central nervous system influences perception, the CB2 receptor in the tissue plays a crucial role in inhibiting inflammation ... Unlike the three psychoactive substances, however, beta-carophyllene does not latch onto the CB1 receptor and consequently does not trigger the intoxicating effect. (Science Daily)
Opioids And Cannabinoids Influence Mobility Of Spermatozoids Jun 25, 2008
Even so, as a consequence of the activation of the CB1 receptor, the number of slow spermatozoids rises, while the activation of CB2 increases the number of spermatozoids with progressive but slow movement. The most effective diagnoses and treatments. (Science Daily)
Marijuana Has Anti-Inflammatory That Won't Get You High Jun 25, 2008
The CB1 receptor is found in and central nervous system and is responsible for the high people experience when they smoke pot. Continued on. (National Geographic)
Pot Plus Alcohol Kills Young Rats' Brain Cells May 2, 2008
The researchers also found that the CB1 receptor blocker drug Rimonabant reduced brain nerve cell death in rats given a combination of THC and ethanol ... The fact that the drug counteracted the effect of THC and ethanol suggests that activation of CB1 receptors may be responsible for the effect that THC has on the neurotoxicity of ethanol, the researchers said ... "The results of the acute studies have interesting potential therapeutic implications for including the use of CB1 receptor... (MEDLINEplus)
High anxiety? Apr 19, 2008
But the findings in the study volunteers suggest that THC and other compounds that act on the CB1 receptors in the amygdala could be fruitful targets for new anti-anxiety medicines. Phan notes that rimonabant, a smoking-cessation and weight-loss drug not yet available in the United States for clinical use, also acts on the CB1 receptor. (EurekAlert!)
Marijuana increases alcohol toxicity in young rats Apr 9, 2008
In addition, marijuana activates CB1 receptor levels, which causes the psychomotor, memory, cognition and pain perception changes seen with this substance in adult humans and animals. In the current study, THC combined with ethanol increased these levels, and the CB1 receptor blocker Rimonabant, an anti-obesity drug that may be beneficial in treating addiction, reduced these levels ... Mice that did not have functioning CB1 receptors (knockout mice) were less susceptible to the neurotoxic... (EurekAlert!)
Cannabinoid-blocking Weight-loss Drug Might Fight Alcoholic Fatty Liver Mar 7, 2008
Studies have also shown that mice lacking CB1 receptors and mice treated with drugs that block these receptors are protected from obesity and fatty liver ... Kunos's team now shows that mice fed a low-fat diet and ethanol show an increase in the gene encoding the CB1 receptor and in liver levels of one endocannabinoid, 2-arachidonoylglycerol (2-AG) ... Similarly, mice lacking CB1 receptors, either throughout the body or only in the liver, gained protection from alcoholic fatty liver. (Science Daily)
Weight-Loss Drug Fights Alcoholic Fatty Liver Disease Mar 5, 2008
And mice lacking CB1 receptors, either throughout the body or only in the liver, were protected from alcoholic fatty liver ... Drugs that selectively act on CB1 receptors found outside of the brain might help fight fatty liver with less risk of side effects such as anxiety and depression, they said ... "Rimonabant has recently been introduced in Europe for the treatment of visceral obesity and the metabolic syndrome, which themselves are known risk factors for [liver disease]. Clinical trials... (Health-Finder)
New Diet Drug in Battle of the Bulge Jan 10, 2008
Early research shows that taranabant helps to suppress appetite and burn fat. FAT CHANCE: A new drug designed to curb appetite is on the horizon. (Scientific American)
Merck sees success with diet pill based on marijuana study Jan 9, 2008
Unlike marijuana, taranabant blocks the CB1 receptor, suppressing appetite. Side effects include anxiety, nausea, vomiting, and frequent bowel movements, according to the study. (Boston Globe)
Anti-obesity Drug May Prevent And Treat Obesity-related Liver Disease Jul 5, 2007
"These data reveal that rimonabant possesses a hepato-protective activity and suggest a new therapeutic role of this CB1 receptor antagonist in hepatic diseases," the authors state ... "This suggests a potential clinical application for this CB1 receptor antagonist in the treatment of liver diseases associated with obesity and the metabolic syndrome.". (Science Daily)
Vernalis plc Initiates a Phase I Trial of a Promising New Approach to Treating Obesity and Related Disorders - Including Type II Diabetes Dec 11, 2006
Blockade of these receptors by selective CB1 receptor antagonists causes weight loss and ameliorates risk factors for obesity related disorders such as cardiovascular disease and type II diabetes. The efficacy of CB1 receptor antagonists in the treatment of obesity, type II diabetes and associated disorders has been clinically demonstrated in recent trials of Rimonabant. (PR Newswire)
Rimonabant Update in the United States Dec 8, 2006
PARIS, Dec. 8 /PRNewswire-FirstCall/ -- Sanofi-aventis announces that concerning the New Drug Application for rimonabant in the United States, the Food and Drug Administration has considered its October 26, 2006 resubmission to be a complete, class 2 response to the FDA February 17, 2006 action letter. The user fee goal date is April 26, 2007. (PR Newswire)
Solvay obesity drug in further phase two trials; payment triggered Dec 8, 2006
BRUSSELS (AFX) - Pharmaceuticals group Solvay SA said its obesity treatment drug SLV319 is to undergo further phase two clinical trials. This decision has triggered a milestone payment of 25 mln usd from commercial partner Bristol-Myers Squibb Co (nyse: - - ), which will be booked in the fourth quarter. (Forbes -- Business)
A Look At FDA-OK'd 'Marijuana' Drug May 19, 2006
The drugs label states that Cesamet, "like other cannabinoids, has complex effects on the central nervous system" and that the drug may work by interacting with cannabinoid receptors (the CB1 receptor) in the brain ... The drugs label states that Cesamet, "like other cannabinoids, has complex effects on the central nervous system" and that the drug may work by interacting with cannabinoid receptors (the CB1 receptor) in the brain. (CBS News)
